Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$0.89
-2.8%		$0.99
$0.81
▼
$3.20
$247.73M0.194.66 million shs2.19 million shs
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
$11.51
$11.66
$11.41
▼
$18.72
$63.37M-0.0414,430 shsN/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$9.69
-1.0%		$13.10
$9.43
▼
$45.00
$237.45M-0.04129,879 shs45,676 shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$3.73
-3.5%		$4.03
$1.29
▼
$5.08
$237.35M1.22960,701 shs210,183 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
+3.83%-1.35%+0.13%-25.81%-66.30%
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
0.00%0.00%0.00%-7.33%-1.37%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
+1.66%-7.03%-31.63%-30.32%-39.72%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
+2.39%+1.58%-3.26%-18.05%+129.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$0.89
-2.8%		$0.99
$0.81
▼
$3.20
$247.73M0.194.66 million shs2.19 million shs
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
$11.51
$11.66
$11.41
▼
$18.72
$63.37M-0.0414,430 shsN/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$9.69
-1.0%		$13.10
$9.43
▼
$45.00
$237.45M-0.04129,879 shs45,676 shs
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$3.73
-3.5%		$4.03
$1.29
▼
$5.08
$237.35M1.22960,701 shs210,183 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
+3.83%-1.35%+0.13%-25.81%-66.30%
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
0.00%0.00%0.00%-7.33%-1.37%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
+1.66%-7.03%-31.63%-30.32%-39.72%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
+2.39%+1.58%-3.26%-18.05%+129.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
2.43
Hold$3.90336.24% Upside
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
2.00
HoldN/AN/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
2.78
Moderate Buy$40.86321.56% Upside
MacroGenics, Inc. stock logo
MGNX
MacroGenics
2.17
Hold$6.3370.02% Upside

Current Analyst Ratings Breakdown

Latest KVAC, AKBA, LYEL, and MGNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/15/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$4.00
9/11/2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/11/2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$44.00
9/8/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Westpark Capital logo
Westpark Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$4.50
8/31/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/17/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/17/2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$9.00 ➝ $11.00
8/14/2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$34.00
8/14/2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/7/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$1.00
(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$219.06M1.13N/AN/A$0.12 per share7.45
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/AN/AN/AN/AN/AN/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$40K5,936.35N/AN/A$11.68 per share0.83
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$149.50M1.59N/AN/A$0.88 per share4.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$5.34M-$0.11N/AN/AN/A-13.54%-88.88%-7.74%11/9/2026 (Estimated)
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$274.45M-$12.83N/AN/AN/A-920,285.25%-91.62%-70.50%11/10/2026 (Estimated)
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$74.62M-$0.22N/AN/AN/A-8.70%-109.26%-18.70%11/11/2026 (Estimated)

Latest KVAC, AKBA, LYEL, and MGNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/A$0.08N/A$0.08N/AN/A
8/13/2026Q2 2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$0.0779$0.31+$0.3879$0.31$59.14 million$32.83 million
8/6/2026Q2 2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$1.94-$1.9180+$0.0220-$1.92$0.00 million$0.00 million
8/5/2026Q2 2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.0420-$0.02+$0.0220-$0.03$48.85 million$49.13 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/AN/AN/AN/AN/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
N/AN/AN/AN/AN/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
0.99
1.43
1.35
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/AN/AN/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
N/A
5.36
5.36
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/A
2.96
2.96

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
51.72%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
66.05%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
96.89%

Insider Ownership

CompanyInsider Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4.30%
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
80.20%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
6.20%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
13.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
194277.11 million265.19 millionOptionable
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/A5.51 million1.09 millionNot Optionable
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
16124.50 million22.99 millionOptionable
MacroGenics, Inc. stock logo
MGNX
MacroGenics
29363.70 million55.04 millionOptionable

Recent News About These Companies

2,488,252 Shares in MacroGenics, Inc. $MGNX Acquired by Bank of America Corp DE
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-2488252-shares-in-macrogenics-inc-mgnx-acquired-by-bank-of-america-corp-de-2026-09-26/
Avidity Biosciences (NASDAQ:RNA) vs. MacroGenics (NASDAQ:MGNX) Head to Head Comparison
September 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31044804
MacroGenics stock holds at USD 4.12 as cash strength stands out
September 23, 2026  |  ad-hoc-news.deA
MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Brokerages
September 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31038894
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Hold" from Analysts
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-macrogenics-inc-nasdaq-mgnx-receives-consensus-recommendation-of-hold-from-analysts-2026-09-22/
MacroGenics stock edges lower as biotech analysts highlight risk and upside
September 19, 2026  |  ad-hoc-news.deA
MacroGenics consensus price target rises 12% to $9.52
September 14, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/macrogenics-consensus-price-target-rises-12-to-952/ar-AA2cbGur
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3359059/0/en/macrogenics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference.html
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944341-macrogenics-inexpensive-adctce-biotech-with-multiple-catalysts-ahead
BlackRock Inc. Takes $21.62 Million Position in MacroGenics, Inc. $MGNX
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-takes-2162-million-position-in-macrogenics-inc-mgnx-2026-09-03/
MacroGenics (NASDAQ:MGNX) VP Sells $129,085.75 in Stock
August 21, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-mgnx-insider-buying-and-selling-2026-08-21/
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
August 20, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2977528/is-macrogenics-mgnx-stock-outpacing-its-medical-peers-this-year?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_1-2977528
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
August 13, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2974683/macrogenics-mgnx-reports-q2-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2974683
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344913/0/en/macrogenics-reports-second-quarter-2026-financial-results-streamlined-operating-model-and-strengthened-financial-position.html
MacroGenics, Inc.: MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program
August 12, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69283109-macrogenics-inc-macrogenics-announces-achievement-of-dollar-10-million-milestone-following-gilead-s-exercise-of-option-to-license-preclinical-bispecific-399.htm
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program
August 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/11/3343155/0/en/macrogenics-announces-achievement-of-10-million-milestone-following-gilead-s-exercise-of-option-to-license-preclinical-bispecific-program.html
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important
July 27, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4925873-macrogenics-whipsaws-on-clinical-data-but-the-big-picture-is-still-important
MacroGenics Advances MGC026 in Phase 1 Oncology Trial
July 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MGNX/pressreleases/3454871/macrogenics-advances-mgc026-in-phase-1-oncology-trial/
MacroGenics slips after early-stage trial data for lead asset
July 24, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4618238-macrogenics-slips-trial-data-lead-asset
MacroGenics, Inc.: MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
July 24, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69114745-macrogenics-inc-macrogenics-provides-clinical-update-on-ongoing-phase-1-study-for-mgc026-399.htm
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
July 23, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/07/23/10419598.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$0.89 -0.03 (-2.83%)
As of 01:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Keen Vision Acquisition stock logo

Keen Vision Acquisition NASDAQ:KVAC

$11.51 0.00 (0.00%)
As of 09/30/2026

Keen Vision Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, and related business combination with one or more businesses or entities. It also intends to focus on businesses in the biotechnology, consumer goods, and agriculture sectors. The company was incorporated in 2021 and is based in Summit, New Jersey.

Lyell Immunopharma stock logo

Lyell Immunopharma NASDAQ:LYEL

$9.66 -0.13 (-1.28%)
As of 01:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

MacroGenics stock logo

MacroGenics NASDAQ:MGNX

$3.72 -0.14 (-3.50%)
As of 01:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas